Trial Profile
Phase 2 Study of MK-3475 in Patients With Microsatellite Unstable (MSI) Tumors
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Adenocarcinoma; Colon cancer; Colorectal cancer
- Focus Therapeutic Use
- 20 Dec 2019 Status changed from recruiting to completed.
- 06 May 2019 Results (n=19) assessing immune related gene expression of colon tumor in metastatic colorectal cancer patients who responded and who did not respond to anti PD-1 therapy, the published in the Clinical Cancer Research.
- 28 Aug 2017 Planned End Date changed from 1 Oct 2020 to 1 Jun 2021.